Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Vertex Among 9 Stocks To Watch In Struggling Market
03:19pm, Monday, 03'rd Oct 2022
As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's
4 Analysts Have This to Say About Neurocrine Biosciences
02:43pm, Monday, 26'th Sep 2022 Benzinga
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
3
0
0
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
02:02pm, Monday, 26'th Sep 2022 Benzinga
Upgrades
According to B of A Securities, the prior rating for Ameresco Inc (NYSE:AMRC) was changed from Neutral to Buy. For the second quarter, Ameresco had an EPS of $0.62, compared to year-ago quart
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
08:00am, Saturday, 24'th Sep 2022
S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared fi
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms
08:48am, Saturday, 17'th Sep 2022
S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market. The post S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed L
SAN DIEGO , Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence
15 Stocks Billionaire Investors Agree It's Smart To Buy Now
08:00am, Monday, 12'th Sep 2022
Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.
3 Growth Stocks That Are Crushing It This Year
02:45pm, Saturday, 10'th Sep 2022 The Motley Fool
These three biotech companies have bucked the trend of declining shares prices in their sector.
3 Growth Stocks That Are Crushing It This Year
10:45am, Saturday, 10'th Sep 2022
These three biotech companies have bucked the trend of declining shares prices in their sector.
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
04:01pm, Tuesday, 06'th Sep 2022
SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m.
Neurocrine Leads 5 Stocks To Watch In Sickly Market
08:00am, Saturday, 03'rd Sep 2022
Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market. The post Neurocrine Leads 5 Stocks To Watch In Sickly Market app
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Neurocrine Biosciences Goes Dumpster-Diving To Accelerate Its International Business Development
11:50am, Wednesday, 31'st Aug 2022
Neurocrine is acquiring beaten-down Diurnal Group for $57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody (commercial
Neurocrine Is Seeing A Very Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin
12:36pm, Monday, 08'th Aug 2022
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%. Management announced that '104 failed to show meaningful efficacy in a Pha
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
08:30am, Friday, 05'th Aug 2022 The Motley Fool
NBIX earnings call for the period ending June 30, 2022.
